Serina Therapeutics, Inc. (SER) SEC filings

SERNYSEPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 2/30

$1.41−0.09 (-6.00%)

Close on Nov 12, 2026Market cap $35.81MP/E –Yield –

SEC filings

40 of Serina Therapeutics's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Current report	8-K	Nov 12, 2026	Nov 12, 2026	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2026	Nov 12, 2026	SEC EDGAR
Current report	8-K	Oct 5, 2026	Oct 9, 2026	SEC EDGAR
Current report	8-K	Sep 9, 2026	Sep 9, 2026	SEC EDGAR
Current report	8-K	Aug 21, 2026	Aug 27, 2026	SEC EDGAR
Current report	8-K	Aug 13, 2026	Aug 13, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Aug 13, 2026	SEC EDGAR
Current report	8-K	Jul 19, 2026	Jul 23, 2026	SEC EDGAR
Current report	8-K	Jul 22, 2026	Jul 22, 2026	SEC EDGAR
Current report	8-K	Jun 17, 2026	Jun 24, 2026	SEC EDGAR
Current report	8-K	May 14, 2026	May 14, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	May 14, 2026	SEC EDGAR
Proxy statement	DEF 14A	Apr 27, 2026	Apr 27, 2026	SEC EDGAR
Current report	8-K	Apr 15, 2026	Apr 21, 2026	SEC EDGAR
Annual report, amended	10-K/A	Dec 31, 2025	Mar 27, 2026	SEC EDGAR
Current report	8-K	Mar 25, 2026	Mar 25, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Mar 25, 2026	SEC EDGAR
Current report	8-K	Mar 17, 2026	Mar 23, 2026	SEC EDGAR
Current report	8-K	Jan 27, 2026	Jan 28, 2026	SEC EDGAR
Current report	8-K	Jan 9, 2026	Jan 15, 2026	SEC EDGAR
Current report	8-K	Dec 10, 2025	Dec 10, 2025	SEC EDGAR
Current report	8-K	Nov 13, 2025	Nov 13, 2025	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2025	Nov 13, 2025	SEC EDGAR
Current report	8-K	Nov 7, 2025	Nov 12, 2025	SEC EDGAR
Current report	8-K	Nov 3, 2025	Nov 3, 2025	SEC EDGAR
Current report	8-K	Oct 6, 2025	Oct 6, 2025	SEC EDGAR
Proxy statement	DEF 14A	Sep 26, 2025	Sep 26, 2025	SEC EDGAR
Current report	8-K	Sep 9, 2025	Sep 15, 2025	SEC EDGAR
Current report	8-K	Sep 9, 2025	Sep 9, 2025	SEC EDGAR
Current report	8-K	Aug 25, 2025	Aug 25, 2025	SEC EDGAR
Current report	8-K	Aug 18, 2025	Aug 22, 2025	SEC EDGAR
Current report	8-K	Aug 11, 2025	Aug 11, 2025	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2025	Aug 11, 2025	SEC EDGAR
Current report	8-K	Jul 29, 2025	Jul 29, 2025	SEC EDGAR
Current report	8-K	Jul 1, 2025	Jul 1, 2025	SEC EDGAR
Current report	8-K	May 22, 2025	May 22, 2025	SEC EDGAR
Current report	8-K	May 8, 2025	May 8, 2025	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2025	May 8, 2025	SEC EDGAR
Current report	8-K	Apr 25, 2025	Apr 29, 2025	SEC EDGAR
Current report	8-K	Apr 15, 2025	Apr 15, 2025	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in Serina Therapeutics's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is SER.

Compare: SER vs LSTA · SER vs CLNN · SER vs SNGX · SER vs IXHL · SER vs HIND

Revenue growth132.1% · median -55.6%

Operating margin-18478.5% · median -8928.6%

Net margin-18843.1% · median -11271.4%

Company	Revenue	Growth
CLNN	$238.00K	+11.2%
HIND	$153.10K	-55.6%
SER	$130.00K	+132.1%
LSTA	$100.00K	-90.7%
SNGX	–	–
IXHL	–	–

Company

Exchange: NYSE
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 16
Held by institutions: 5.5%
Auditor: Frazier & Deeter, LLC
SEC CIK: 1708599

Advertisement
300 × 250

See a number that looks wrong?